SCHEMBL13991879

SCHEMBL13991879

CCC(=O)C(=O)NCCCC(=O)OC(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ EPHX2 P34913 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.41
▸ PLA2G4A P47712 1/20 0.41
▸ PLA2G2A P14555 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ SLC25A20 O43772 3/20 0.36
▸ TP53 P04637 2/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ THPO P40225 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13286569 0.82 TSHR (0.52) LMNAEPHX2ALDH1A1PLA2G4APLA2G2A
SCHEMBL13991878 0.79 CYP1A2 (0.48) EPHX2ALDH1A1PLA2G4ACYP2D6KDM4E
SCHEMBL5808280 0.79 LMNA (0.53) LMNAEPHX2ALDH1A1MAPTMAPK1
SCHEMBL13991880 0.77 EPHX2 (0.44) EPHX2PLA2G4APLA2G2AMEN1KMT2A
SCHEMBL13991921 0.76 TSHR (0.55) LMNAEPHX2ALDH1A1PLA2G4APLA2G2A
SCHEMBL26253430 0.75 MEN1 (0.50) PLA2G4APLA2G2AMAPK1KDM4EMEN1
SCHEMBL27372304 0.75 LMNA (0.58) LMNAEPHX2ALDH1A1MAPTMAPK1
SCHEMBL13991911 0.75 ALDH1A1 (0.51) EPHX2ALDH1A1PLA2G4APLA2G2ACYP3A4
SCHEMBL13286572 0.74 PLA2G4A (0.68) EPHX2ALDH1A1PLA2G4APLA2G2AMAPT
SCHEMBL8851730 0.74 LMNA (0.57) LMNAEPHX2ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319065-A1 Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319065-A1 Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release PLA2G4A, PLA2G4B, PLA2G2A LMNA 2391/4885EPHX2 140/4885ALDH1A1 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback